Microbial limits (bioburden)
USP <61> enumerates microbial load; USP <62> evaluates specified microorganisms under the stated test conditions.
QBio · Quality
Compliance anxiety is the quiet objection in this category. Rather than wait for the diligence email, we have put the answers — including the uncomfortable ones — on a public page.
Lot-level documentation
Enter the lot number exactly as it appears on the vial or package.
Release testing
USP <61>, USP <62>, and USP <85> are performed by an independent laboratory on every batch. Results are recorded on that lot’s certificate of analysis.
USP <61> enumerates microbial load; USP <62> evaluates specified microorganisms under the stated test conditions.
A compendial test used to evaluate bacterial endotoxin against the release specification for the lot.
Testing is performed by an independent laboratory on every batch, and the results are recorded on that lot’s certificate of analysis.
Regulatory position
In plain language, without the hedging this category is known for.
No. There are no FDA-approved exosome products, for any indication, from any company. Any supplier telling you otherwise is either mistaken or misleading you. QBio products are topical cosmetics for professional use — not drugs, not biologics, and not approved therapies.
It means the manufacturing establishment is registered with the FDA. It is a registration, not an approval, and it says nothing about whether any particular product has been reviewed or cleared. We state it because it is true and relevant to how the product is made — not as a substitute for approval we do not have.
No. QBio products are for topical use only. They are not intended for injection or intravenous delivery, and we do not supply them for that purpose. This is stated on the product, in the Application Procedure and in the footer of every page on this site.
Appearance-based cosmetic claims only. We describe how the product is used and what is measurably in it. Where we discuss biology, we are describing published literature about ingredients — not asserting what the finished product does to anyone. We do not make therapeutic claims, and we ask our providers not to make them on our behalf.
Every batch undergoes third-party microbial limits testing to USP <61> and USP <62>, and bacterial endotoxin testing to USP <85>. Results are recorded on the lot certificate of analysis, which you can look up by lot number on this page.
Responsible claims
We hold ourselves to three rules, and we would rather lose a sale than break them.
We describe how something looks, not what it does biologically to a person.
We publish the analytical identity, concentration, method, and laboratory reported in the characterization documentation.
Not in our copy, not in our sales conversations, and — we ask — not in yours. Our Case Submission Kit includes a brand usage sheet covering what not to say, because a provider making a drug claim about our product is our problem too.
Ethical sourcing
Our sourcing page publishes the donor-eligibility review and infectious-disease screening panel behind qualified perinatal-tissue inputs.
Document library
Public documents remain public. Commercial documents are provided through the professional conversation.
Full quantified protein tables for Elixir and Gro, with the third-party laboratories named.
Open the data →PublicPre-clinical studyComplete in vitro methods, results and references, organized for direct professional review.
Read the study →PublicLot certificatesMicrobial limits and endotoxin results, searchable by lot number.
COA lookup →On requestRegulatory position memoOur counsel-reviewed position, for your compliance file.
Request it →On requestFull evidence dossierEverything above in one forwardable document. No pricing in it.
Request the dossier →With your orderStandard Application ProceduresStep-by-step reconstitution and application, per product.
See the protocols →